Nippon Soda Co., Ltd.

Toray Industries, Inc.

Osaka Prefecture University Public Corporation

Kenichi Hayashi

Mie Kaino

Makoto Toyooka

Hideki Inoue

Noriyuki Hirano

Hiroyuki Meguro

Takahiro Sagae

Masamichi Yasuhara

Hideki Maekawa

Ilhyong Ryu

Toshiaki Nishizawa

Masaaki Sato

Asami Kohori

Masahiro Hori

Hiroyuki Nishijima

Ryutaro Suzuki

Sunao Hara

Tomofumi Ohyama

Takashi Nagahara

Souichiro Kyushin

An object of the present invention is to provide a method for producing a bis(fluorosulfonyl)amide alkali metal salt powder having high purity while suppressing reduction in yield due to thermal decomposition, etc. The method for producing a bis(fluorosulfonyl)amide alkali metal salt powder according to the present invention comprises precipitating a bis(fluorosulfonyl)amide alkali metal salt by conducting distillation using a thin-film evaporator while adding a poor solvent for the bis(fluorosulfonyl)amide alkali metal salt such as an aromatic hydrocarbon solvent and a linear or branched aliphatic hydrocarbon solvent to a solution formed by dissolving the bis(fluorosulfonyl)amide alkali metal salt in a good solvent for the bis(fluorosulfonyl)amide alkali metal salt such as an ester solvent and nitrile solvent.

Method for producing bis(fluorosulfonyl)amide alkali metal salt powder

An organic polysilane, which can produce signals respectively derived from a Si&#x2014;O bond, an alkoxy group and a hydroxy group at levels equal to or lower than the detection limits inSi andC CP/MAS NMR analysis, can be produced by a method which includes: polymerizing an organic dihalosilane in an aprotic solvent in the presence of an alkali metal and/or an alkali earth metal to produce a mixture containing an organic polysilane having a terminal halogeno group; adding a solution containing an organic lithium compound and an aprotic polar solvent to the mixture to inactivate the organic polysilane having the terminal halogeno group; and then adding a protic polar solvent to the resultant mixture to deactivate the alkali metal and/or the alkali earth metal.

Method for producing organic polysilane

The present invention provides: a method for producing particles of an element having a standard electrode potential greater than 0V, characterized by using in a protic solvent solution a polysilane having a poor solubility in an aprotic solvent, to produce particles of the element from ions of at least one element having a standard electrode potential greater than 0V; and a composite body of polysilane and the particles of an element having a standard electrode potential greater than 0V, in which the particles of the at least one element having a standard electrode potential greater than 0V (provided that palladium is not included in the element, in the case where the polysilane is a dimethyl polysilane) are adsorbed in the polysilane having poor solubility in an aprotic solvent.

Production method for particles of element having standard electrode potential greater than 0V

The present invention provides a polydialkylsilane, and a method for producing a polydialkylsilane, including a step of adding a compound represented by formula (I) (in formula (I), Rand Rindependently represent an alkyl group, and Xand Xindependently represent a halogen atom) to an organic solvent containing an alkali metal, in which 0.010 [hr]&#x2266;the average addition rate of compound (I) [moles&#xb7;hr]/the amount of the alkali metal [moles]&#x2266;0.055 [hr]. 

Method for producing polydialkylsilane

This invention provides a microreactor comprising a microchamber provided with a raw material introduction port and a product discharge port; wherein solid catalysts are aligned in a line in the longitudinal direction of the microchamber to fill the microchamber.

Microreactor and liquid phase chemical reaction method using microreactor

A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects. 

Therapeutic or prophylactic agent for multiple sclerosis

The compounds of the disclosure, for example, the compound represented by the formula: has excellent therapeutic and prophylactic effects against inflammatory bowel disease. Further, they are excellent in absorption and in vivo stability when administered orally in comparison with conventional compounds. That is, the compounds can be administered orally, and can have excellent therapeutic or prophylactic effect sustained for a longer period of time.

Glycine derivative and use thereof

Growing community of inventors

Joetsu, Japan

Kenichi Hayashi